PP209 – Clinical Practice Guideline Management Type 2 DM in Primary Care
Case managers play a critical role facilitating patient care needs to include patients with Type 2 Diabetes Mellitus. Since the release of the U.S. Department of Veterans Affairs (VA) and Department of Defense Clinical Practice Guideline (CPG) for the Management of Type 2 Diabetes Mellitus in Primary Care (DM), a growing body of research has expanded the general knowledge and understanding of DM. Improved recognition of the complexities of this condition has led to the adoption of new strategies for diagnosis and treatment of patients with Type 2 DM. The VA/DoD CPG for the Management of Type 2 Diabetes Mellitus in Primary Care Version 5.0 was released in Apr 2017 to provide health care providers with a framework by which to diagnosis, treat, and manage the needs of patients with LBP. The revised CPG incorporates objective, evidence-based recommendations from the VA/DoD Management of Type 2 Diabetes Mellitus work group.
This presentation will briefly review the purpose of a CPG and discuss the CPG key recommendations. In addition, the presentation will focus on the importance of patient-centered treatment planning and shared decision-making; education and self-care; non-pharmacologic and non-invasive therapy and pharmacology treatment recommendations. The presentation will conclude by identifying the additional clinical support tools available for providers, patients, and family members to help attendees implement these evidence-informed recommendations in their practice.
1. Discuss the risk factors for patients who are at higher risk for type 2 diabetes
2. Discuss shared decision making to enhance patient knowledge, satisfaction and outcomes and offering therapeutic lifestyle changes counseling that includes nutrition, physical activity, cessation of smoking and excessive use of alcohol, and weight control to patients with diabetes
3. Discuss an individualized target range for HbA1c taking into account individual preferences, presence or absence of microvascular complications, and presence or severity of comorbid conditions